TIGIT and neoplasm: That is, TIGIT expression in effector T cells increased via TCR signaling pathways, which can be activated by PD-1 blockade,32 in the inflamed TME, and such TIGIT+ effector T cells were subsequently suppressed by CD155 expressed in tumor cells, leading to the survival of CD155-expressing tumor cells and resistance.